Aurinia Pharmaceuticals annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals's operating margin was 37.06% for fiscal 2025.
View full Aurinia Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 37.06% | +39.06 pp |
| 2024 | 2024-12-31 | −1.99% | +50.25 pp |
| 2023 | 2023-12-31 | −52.24% | +30.93 pp |
| 2022 | 2022-12-31 | −83.17% | +313.14 pp |
| 2021 | 2021-12-31 | −396.31% | −188.22 pp |
| 2020 | 2020-12-31 | −208.09% | +28390.34 pp |
| 2019 | 2019-12-31 | −28,598.43% | −16667.54 pp |
| 2018 | 2018-12-31 | −11,930.89% | −718.45 pp |
| 2017 | 2017-12-31 | −11,212.44% | +3254.03 pp |
| 2016 | 2016-12-31 | −14,466.47% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 55.68% | +27.00 pp |
| Q1 2026 | 2026-03-31 | 53.31% | +18.33 pp |
| Q4 2025 | 2025-12-31 | 43.10% | +45.89 pp |
| Q3 2025 | 2025-09-30 | 40.49% | +23.15 pp |
| Q2 2025 | 2025-06-30 | 28.69% | +31.33 pp |
| Q1 2025 | 2025-03-31 | 34.97% | +61.32 pp |
| Q4 2024 | 2024-12-31 | −2.79% | +63.02 pp |
| Q3 2024 | 2024-09-30 | 17.33% | +47.17 pp |
| Q2 2024 | 2024-06-30 | −2.65% | +36.32 pp |
| Q1 2024 | 2024-03-31 | −26.35% | +59.63 pp |
| Q4 2023 | 2023-12-31 | −65.80% | +33.02 pp |
| Q3 2023 | 2023-09-30 | −29.83% | −12.80 pp |
| Q2 2023 | 2023-06-30 | −38.97% | +88.69 pp |
| Q1 2023 | 2023-03-31 | −85.98% | +89.20 pp |
| Q4 2022 | 2022-12-31 | −98.82% | +40.92 pp |
| Q3 2022 | 2022-09-30 | −17.03% | +326.28 pp |
| Q2 2022 | 2022-06-30 | −127.66% | +584.33 pp |
| Q1 2022 | 2022-03-31 | −175.18% | +5354.69 pp |
| Q4 2021 | 2021-12-31 | −139.74% | −123.65 pp |
| Q3 2021 | 2021-09-30 | −343.31% | +145570.48 pp |
| Q2 2021 | 2021-06-30 | −711.99% | +91919.04 pp |
| Q1 2021 | 2021-03-31 | −5,529.87% | +84670.13 pp |
| Q4 2020 | 2020-12-31 | −16.09% | — |
| Q3 2020 | 2020-09-30 | −145,913.79% | — |
| Q2 2020 | 2020-06-30 | −92,631.03% | — |
| Q1 2020 | 2020-03-31 | −90,200.00% | — |
Over the last five reported fiscal years, Aurinia Pharmaceuticals's operating margin increased from −208.09% to 37.06%, a change of +245.15 percentage points. The latest reported quarter, Q2 2026, shows 55.68%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals filings at SEC.gov ↗